The emerging era of pharmacogenomics: current successes, future potential, and challenges
Lee, JW Aminkeng, F Bhavsar, AP Shaw, K Carleton, BC Hayden, MR Ross, CJD
Lee, JW
Bhavsar, AP
Shaw, K
Carleton, BC
Hayden, MR
Ross, CJD
Citations
Altmetric:
Alternative Title
Abstract
The vast range of genetic diversity contributes to a wonderful array of human traits and characteristics. Unfortunately, a consequence of this genetic diversity is large variability in drug response between people, meaning that no single medication is safe and effective in everyone. The debilitating and sometimes deadly consequences of adverse drug reactions (ADRs) are a major and unmet problem of modern medicine. Pharmacogenomics can uncover associations between genetic variation and drug safety and has the potential to predict ADRs in individual patients. Here we review pharmacogenomic successes leading to changes in clinical practice, as well as clinical areas probably to be impacted by pharmacogenomics in the near future. We also discuss some of the challenges, and potential solutions, that remain for the implementation of pharmacogenomic testing into clinical practice for the significant improvement of drug safety. © 2014 The Authors. Clinical Genetics published by JohnWiley & Sons A/S. Published by JohnWiley & Sons Ltd..
Keywords
Science & Technology, Life Sciences & Biomedicine, Genetics & Heredity, ADRs, adverse drug reactions, anthracycline, carbamazepine, cisplatin, codeine, pharmacogenomics, warfarin, ANTHRACYCLINE-INDUCED CARDIOTOXICITY, IMPLEMENTATION CONSORTIUM GUIDELINES, WARFARIN DOSE REQUIREMENT, ADVERSE DRUG-REACTIONS, GENETIC POLYMORPHISMS, HEARING-LOSS, CHILDREN, CODEINE, CYP2C9, CHILDHOOD
Source Title
CLINICAL GENETICS
Publisher
WILEY
Series/Report No.
Collections
Rights
Date
2014-07-01
DOI
10.1111/cge.12392
Type
Review